Hematopoietic Stem Cell Transplantation for Aplastic Anaemia : Outcomes from Argentine Group of Haematopoietic Stem cell transplant (GATMO)

MILOVIC, V; ROBERTI, JAVIER

Estambul

Congreso; 41st Annual Meeting of the European Society for Blood and Marrow Transplantation; 2015

Hematopoietic Stem Cell Transplantation for Aplastic Anaemia : Outcomes from Argentine Group of Haematopoietic Stem cell transplant (GATMO)V. Milovic1,*, A. Basquiera2, J. Garc ́ıa2, S. Formisano2,R. Ferna ́ndez2, G. Jaimovich2, G. Kuminsky2, J. Milone2, M. Rivas2, S. Yantorno2, J. Jarchum2, M. Rizzi2, J. Mart ́ınez Rolo ́n2,C. Foncuberta2, R. Burgos2, G. Balladares2, S. Saba2,G. Drelichman2, J. Real2, L. Feldman2, J. E. Roberti11Hospital Aleman, 2GATMO, Buenos Aires, ArgentinaIntroduction: Acquired aplastic anaemia (AAA) is a serious and rare disease characterised by peripheral blood pancyto- penia, bone marrow aplasia or hypoplasia. For patients with severe and very severe AAA younger than 40 years of age, hematopoietic stem cell transplantation (HSCT) is the treat- ment of choice. The use of ATG/Cyclosphosphamide (Cy) conditioning regimen has been associated with a 5-year survival rate of 60-90%. Since 2002, rATG is the only available ATG in the Argentine market. We describe the outcomes of HSC transplantation (tx) in pts with AAA, who received rATG/ Cyclophosphamide (Cy) as conditioning regimenMaterials (or patients) and methods: Retrospective cohort study. We analysed data from 84 transplants performed in 82 pts between 1998-2014 in 11 Argentine centres. Patients: Mean age at transplant was 19.264±10.09 years; 46(55%) pts were o20 years old, and 36(43%) were 420 years old. Median interval from diagnosis to transplant was 141(21-4429) days. Nineteen patients (25%) had received a previous treatment, 3(3.4%) were second transplants; 74(88%) patients received HSC from related donors; the source of HSC was: bone marrow in 56(68%), and peripheral blood in 21(25.6%) patients. Mean infused cell dose was 4.3±3x106/kg.Results: Median time to neutrophil count41000/mm3 was 20(9-42) days, and to platelet count 420000/mm3 was 23(11- 108) days. Four (4.8%) patients had early rejection and 4(4.8%) had late graft rejection, with a median time to rejection of 371(137-745) days in the late rejection group. Seven (8.3%) patients developed cGvH, with no significant difference according to SC source. With a median follow-up of 823(1- 4429) days, 23(28%) patients died; the main cause of death was infection in 15(71%) cases. The overall survival at 100, 365 and 4429 days was 89%(CI80-94), 79%(CI68-86) and 67%(CI54-77), respectively, without statistically significant difference between age groups.Conclusion: Most patients with AAA were able to receive SCT as the first line therapy, with a low early graft rejection rate. Overall survival and cGvH rate are similar to those reported internationally.Disclosure of Interest: None declared.